Award

National Cancer Institute 5R01CA272934-04

WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer

Recipient

Beth Israel Deaconess Medical Center, Boston, MA, United States

Award Amount

$395,509.00

Ceiling

$395,509.00

Awarded

May 26, 2026

Identifier

5R01CA272934-04

This award funds a research project focused on understanding how Wnt5a/ROR2 signaling activates the Hippo pathway to suppress tumor growth in prostate cancer, with the goal of developing targeted therapies using Wnt5a-mimetic drugs for certain prostate cancer patients.

Description

Research project investigating the role of Wnt5a/ROR2 signaling in activating the Hippo pathway to suppress YAP1/TAZ activity in prostate cancer, aiming to identify biomarkers and assess therapeutic potential of Wnt5a-mimetic drugs for metastatic castration-resistant prostate cancer (mCRPC).

View original record